{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-085545","form_type":"8-K","ticker":"XOMA","cik":"0000791908","company_name":"XOMA Royalty Corp","filed_at":"2024-04-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:21.983891+00:00","generated_at":"2026-06-04T03:06:38.661852+00:00","sec_items":["2.01","8.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"XOMA completes acquisition of Kinnate Biopharma for $2.5879 per share plus CVRs","bullets":["XOMA purchased ~81% of Kinnate shares via tender offer at $2.5879/share plus one CVR per share.","Merger closed under DGCL Section 251(h); remaining shares converted to same consideration.","CVRs entitle holders to potential payments from future disposition of Kinnate's products within one year, up to five years.","Total of 38,258,681 shares tendered; all conditions satisfied for merger.","XOMA expects to realize value from Kinnate's pipeline; CVR agreement filed as exhibit."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-085545","json":"https://secwatch.observer/filing/0001193125-24-085545.json","markdown":"https://secwatch.observer/filing/0001193125-24-085545.md","text":"https://secwatch.observer/filing/0001193125-24-085545.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/791908/000119312524085545/0001193125-24-085545-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/791908/000119312524085545/d793644d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T03:06:38.661852+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ebc701e70ea5c5b4c5e59b465f1d995c06ce17e5","claim":"XOMA Royalty Corp completed an acquisition involving Kinnate Biopharma Inc. for $2.5879 in cash per Share plus one non-transferable contractual contingent value right per Share (closed 2024-04-03).","evidence_excerpt":"April 3, 2024, XOMA completed a tender offer to purchase all of Kinnate’s outstanding shares of common stock, par value $0.0001 per share (the “ Shares ”), in exchange for (i) $2.5879 in cash per Share (the “ Cash Amount ”), plus (ii) one non-transferable contractual contingent value right per Share (each, a “ CVR ” and each CVR together with the Cash Amount,","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/791908/000119312524085545/0001193125-24-085545-index.htm","confidence":0.9,"family_label":"M&A Transactions","details":[{"label":"Action","value":"acquisition"},{"label":"Counterparty","value":"Kinnate Biopharma Inc."},{"label":"Consideration","value":"$2.5879 in cash per Share plus one non-transferable contractual contingent value right per Share"},{"label":"Closing","value":"2024-04-03"}],"fact_type":"ma_transaction"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}